Evolutionary malignant resistance of cells to damaging factors as common biological defence mechanism in neoplastic development. Review of conception

Journal of Experimental and Clinical Cancer Research

Volumn 19, Issue 3, 2000, Pages 335-348

  Monceviciute Eringiene, E ^a  

^a Vilnius   (Lithuania)

Author keywords

Atavism; Glutathione S transferase; Inborn and acquired resistance; MDR; Microorganisms; MXR; P glycoprotein; Somatic and tumour cells; Trypan blue; Tumour accelerated growth

Indexed keywords

GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P;

ANIMAL CELL; ARTICLE; CANCER RESISTANCE; CARCINOGENESIS; CELL SURVIVAL; DEFENSE MECHANISM; METASTASIS; MULTIDRUG RESISTANCE; MUTATION; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH; TUMOR REGRESSION;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; CARCINOGENS; DEFENSE MECHANISMS; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GLUTATHIONE TRANSFERASE; HUMANS; IMMUNIZATION; MODELS, BIOLOGICAL; NEOPLASMS; P-GLYCOPROTEIN; RATS; SARCOMA; TRYPAN BLUE; TUMOR CELLS, CULTURED; XENOBIOTICS;

EID: 0033765036     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (98)

1. Immunological investigation of oncological risk and of cancer patients
2. Smoking, alcohol, immunity and cancer. Vilnius: Mokslas
3. Smoking, immunosuppression and cancer
4. Newness in the etiopathogenetical mechanisms of cancer
5. Disturbance of human immune state as possible oncological risk factors
6. Influece of industrial and ecological factors on blood producing and immune sistems
7. Immunologic theory of aging: Current status
8. Aging and immunity
9. Ethanol immune responses, and murine AIDS: The role of vitamin E as an antioxidant
10. Significance of active and passive prevention of cancer, arteriosclerosis and senility
11. Cancer and malignant resistance of cells as fenomena of adaptation to damaging factors
12. On the resitance of cells to damaging factors
13. Cancer as a special case of the resistance of cells to injuring factors
14. Deletion mapping of a locus on human chromosome 22 involved in the oncogenesis of meningioma
15. Clonal genomic alterations in glioma malignancy stages
16. Constitutional deletions predisposing to retinoblastoma
17. Loss of constitutional heterozygosity in human cancer
18. The role of antibiotics in the evolution of microorganisms. A Review
19. The change of microflora in association by antibiotico-therapy of festering peritonits
20. The mechanisms of the pathogenicity of bacteria in different infections
21. Ultrastucture of organization L-form brucell and cultures of reverters
22. Yersinia L-transformation in experimental pseudotuberculosis
23. Growth and adhesion of Enterococcus faecium L-forms
24. Experimental otitis media induced by coagulase negative Staphylococcus and its L-forms
25. Insauts antimicrobial resistance
26. New pathogens and old resistence genes
27. Evolution of resistance in microorganisms of human origin
28. Problems and dilemms of antimicrobial resistance
29. The role of the MDRI (P-glycoprotein gene) in multidrug resistance in vitro and in vivo
30. Mechanism of resistance to azole antifungals
31. A bacterial antibiotic-resistance gene that complements the man multidrug-resistance P-glycoprotein gene
32. The ABC family of multidrug transporters in microorganisms
33. The chemosensitizers of multixenobiotic resistance mechanism in aquatic invertebrates: A new class of pollutants
34. Multidrug resistance: Molecular biology and clinical relevance
35. Modes of resistance to antitumor agents
36. On the reciprocal ratio of precancer change-over and reactive proliferation
37. The influence of carcinogenic substances on sarcomata induced by the same and other compounds
38. Sensitivity of normal and neoplastic cells to the damaging action of cancerogenic substances
39. Cancer: A reactive mechanism in order to save life
40. Phylogenesis-oncogenesis
41. Tumor as reaction of atavistical adaptation on circumstances of surrounding environment
42. Ecological Oncology
43. Evolution, ecology and cancer
44. Phylogeny and oncogeny
45. Oncologic ecology and its goals
46. Cancer and filtrable forms of cells
47. Actual proposition in modern oncology by sanitation of the population
48. Cancer as a phenomenon of accelerated growth expressing the nature of general malignant resistance of adapted cells to damaging factors
49. Resistance of microorganisms and somatic cells to damaging factors
50. A genetic model for colorectal tumorigenesis
51. Transformation of rat liver epithelial cells with v-Ha-ras or v-raf causes expression of MDR-1, glutathione-S-transferase-p and increased resistance to cytotoxic chemicals
52. Pglycoprotein in pathology: The multidrug resistance gene family in humans
53. The war on cancer: A review
54. Cellular adaptation in the origin and development of cancer
55. Cancer screening based on genetic alterations in human tumors
56. Modulation of activity of the promoter of the human MDR 1 gene by Ras and p53
57. Expression of mutated p53 occurs in tumour-distant epithelia of head and neck cancer patients: A possible molecular basis of the development of multiple tumours
58. Detabase and software for the analysis of mutations in the human p 53 gene
59. Endogenic dedifferentiation factors in cell proliferation and malignization
60. About changing the color index by neobenzenol therapy
61. Tumourigenesis, auto- and concomitant immunity in an organism of female after intradermal injection of vital dye trypan blue: 190
62. On treatment of the skin pre-cancerous illness with malkupaz
63. Oncocognitive autoimmunity
64. Dinamica of autoimmune antibodies in growth process of the transplantable tumours in mice
65. Concomitant immunity
66. Games people play: How parasites evade immune surveillance
67. The response of mice immune system to Schistosoma mansoni to a challenge infection wich bypasses the skin: Evidence for two mechanisms of immunity
68. Mechanisms to improve chemotherapy effectiveness
69. Immunohistochemical detection of P- glycoprotein, glutatione S-transferase and DNA topoisomerase II in human tumors
70. Multidrug resistence and behavioural phenotype of cancer cell
71. Resistance to cancer chemotherapy
72. Expression of a multidrug resistance gene in human cancers
73. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene
74. Mechanisms of resistance to alkylating agents and cisplatin
75. Expression of a multidrug resistance gene in human tumors and tissues
76. Multiple drug resistance, the MDR gene, and the law of maximum perversity as it applies to oncology: An hypothesis
77. Glutathione Stransferase in chemotherapy resistance and in carcinogenesis
78. Cellular biochemistry of the stepwise development of cancer with chemicals: GHA Clowes memorial lecture
79. Expression of multidrug resistance-related genes (mdr1, MRP, GST-p and DNA topoisomerase II) in urothelial cancers
80. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: Detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy
81. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia
82. Drug resistance in multiple myeloma
83. Regrowth resistance in cancer: Why has it been largely ignored?
84. Intrinsic or acquired drug resistance and metastasis: Are they linked pheno-types?
85. The limitations and adverse effects of cancer chemotherapy
86. Expression of mdr 1 gene in human breast primary tumors and metastases
87. Overexpression of p 53 is a late event in the development of malignant melanoma
88. Growth dominance of metastatic cancer cell: Cellular and molecular aspects
89. Defining the critical gene expression changes associated with expression and suppression of the tumorigenic and metastatic pheno-type in Ha-ras-transformed cloned rat embryo fibroblast cells
90. The expression of drug resistance gene products during the progression of human prostate cancer
91. Relationship of the expression of the multidrug resistance gene products (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis
92. Clinical significance of P-glycoprotein in multidrug resistance malignancies